Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 16;12(17):3027-3034.
doi: 10.12998/wjcc.v12.i17.3027.

Effect of Luhong formula on the cardiac rehabilitation of patients with chronic heart failure

Ji-Jie Xu  1 , Jian Dai  2 , Qi-Hai Xie  2 , Pei-Chao Du  2 , Cha Li  2 , Hua Zhou  2
Affiliations

Effect of Luhong formula on the cardiac rehabilitation of patients with chronic heart failure

Ji-Jie Xu et al. World J Clin Cases. .

Abstract

Background: Current treatments for chronic heart failure (CHF) are therapeutically ineffective. The optimization of treatments for this disease needs to be explored and analyzed.

Aim: To analyze the effect of using Luhong Formula in the cardiac rehabilitation of patients with CHF and its influence on cardiopulmonary function (CPF) and prognosis.

Methods: In total, 160 patients with CHF admitted between June 2022 and June 2023 were selected, including 75 receiving perindopril (control group) and 85 receiving Luhong Formula (research group). We conducted comparative analyses on the curative effects of traditional Chinese medicine (TCM) syndromes and cardiac function, CPF [oxygen consumption at the anaerobic threshold (VO2 AT) and at peak exercise (peak VO2)], echocardiographic indexes [left atrial volume index (LAVI), left ventricular muscle mass index (LVMI), left ventricular ejection fraction (LVEF)], and prognosis [major adverse cardiovascular events (MACEs) at 6 months follow-up].

Results: The research group showed markedly higher curative effects of TCM syndromes and cardiac function than the control group. In addition, post-treatment VO2 AT, peak VO2, LVMI and LVEF in the research group were significantly higher, whereas LAVI was significantly lower, than those of the control group. Furthermore, fewer patients in the research group developed MACEs at the 6-month follow-up.

Conclusion: Luhong Formula is more therapeutically effective than perindopril for the cardiac rehabilitation of patients with CHF, specifically in enhancing CPF and prognosis.

Keywords: Cardiac rehabilitation; Cardiopulmonary function; Chronic heart failure; Luhong formula; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Dr. Xu has nothing to disclose.

Figures

Figure 1
Figure 1
Comparative analysis of anaerobic threshold and peak exercise before and after intervention. A: Oxygen consumption at the anaerobic threshold (VO2 AT) before and after intervention; B: Oxygen consumption at peak exercise (peak VO2) before and after intervention. aP < 0.05 vs before intervention. bP < 0.01 vs before intervention. cP < 0.05 vs control group. VO2 AT: Oxygen consumption at the anaerobic threshold; Peak VO2: Oxygen consumption at peak exercise.
Figure 2
Figure 2
Comparative analysis of left atrial volume index, left ventricular muscle mass index, and left ventricular ejection fraction before and after intervention. A: Left atrial volume index before and after intervention; B: Left ventricular muscle mass index before and after intervention; C: Left ventricular ejection fraction before and after intervention. aP < 0.05 vs before intervention. bP < 0.01 vs before intervention. cP < 0.05 vs control group. LAVI: Left atrial volume index; LVMI: Left ventricular muscle mass index; LVEF: Left ventricular ejection fraction.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Špinar J, Špinarová L, Vítovec J. Pathophysiology, causes and epidemiology of chronic heart failure. Vnitr Lek. 2018;64:834–838. - PubMed
    1. Vijay K, Neuen BL, Lerma EV. Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities. Cardiorenal Med. 2022;12:1–10. - PubMed
    1. Triposkiadis F, Xanthopoulos A, Parissis J, Butler J, Farmakis D. Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail Rev. 2022;27:337–344. - PubMed
    1. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368–378. - PMC - PubMed
    1. Writing Group Members; Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133:e38–360. - PubMed